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Timeline cluster: a graphical tool to identify risk of bias in cluster 
randomised trials
Agnès Caille,1 ,2 ,3 Sally Kerry,4 Elsa Tavernier,2 ,3 Clémence Leyrat,5 Sandra Eldridge,4 
Bruno Giraudeau1 ,2  ,3 
Robust evidence of the effectiveness of 
interventions relating to policy, 
practice, and organisation of 
healthcare often comes from well 
conducted cluster randomised trials. 
Such trials are, however, prone to 
recruitment bias depending on whether 
participants are recruited before the 
randomisation of clusters and whether 
the recruiter is blinded to the allocation 
status. In most cases, participants and 
trial staff cannot be blinded to the 
intervention, which might lead to 
performance and detection bias. 
Unfortunately, cluster trial reports often 
do not provide a clear description of 
the timing of trial processes and 
blinding, and these aspects are not 
covered by current reporting tools. This 
article proposes a graphical tool 
depicting the time sequence of steps 
and blinding status in cluster 
randomised trials. The tool might be 
helpful at both the protocol and the 
report writing stages to clarify the 
process and to help identify potential 
bias in cluster randomised trials.
In cluster randomised trials, clusters of subjects such 
as hospitals or family practices are randomised rather 
than people themselves.1  Cluster randomised trials 
are used for evaluating health service organisation 
and health policy, often with complex interventions 
targeted at the level of the cluster, the individual, or 
both. Randomisation should prevent allocation bias at 
the cluster level provided that it is properly conducted, 
but differences in individual level characteristics 
between the intervention arms can be reintroduced 
because of the relative timing of participant identifica-
tion and recruitment, and cluster randomisation. 
Indeed, the usual chronology of an individual ran-
domised trial with first recruitment and then randomi-
sation of participants can be reversed in cluster 
randomised trials: the identification and recruitment 
of participants often take place after randomisation, 
which could lead to identification or recruitment bias 
(hereafter called recruitment bias).2 3 Because blinding 
is rarely possible for interventions assessed in cluster 
randomised trials, previous knowledge of the alloca-
tion from recruiters or participants can influence who 
is approached and who agrees to participate in a trial. 
This might lead to different recruitment rates between 
arms as well as imbalance in participant characteris-
tics.4-6 Some solutions proposed to prevent recruit-
ment bias include the identification and recruitment 
of participants before cluster randomisation or recruit-
ment of participants by a blinded and independent 
person.7  These solutions should be considered when-
ever possible, but they are not always feasible or 
applied. Furthermore, cluster randomised trials are 
prone to other biases, usually encountered when 
blinding is lacking—namely, performance bias and 
detection bias.8 Performance bias refers to systematic 
differences between the care delivered to experimental 
and control arms other than the intervention under 
investigation. Knowledge of the allocation by partici-
pants, intervention providers, or other trial staff leads 
to a risk of performance bias by contamination (with 
delivery of one of the trial interventions in clusters, or 
participants allocated to receive the other interven-
tion) or by difference in the delivery of cointerven-
tions. Because cluster randomised trials are 
pragmatic, the control arm often consists of usual care 
(or no intervention). Thus a particular attention might 
be paid to information provided to participants and 
care providers in this group, in that precise informa-
tion about the experimental intervention could 
change their behaviour during the trial and lead to 
contamination. Detection bias refers to systematic dif-
ferences between arms in how outcomes are assessed. 
As in individual randomised trials, in cluster ran-
domised trials,  knowledge of the allocation by out-
come assessors can affect outcome measurement, in 
particular when outcome measurement involves some 
Summary pointS
Cluster randomised trials can be at risk of bias when participants are identified and 
recruited after randomisation
Reports of cluster randomised trials often fail to adequately describe the 
recruitment process and whether participants and trial staff are blinded to 
allocation status at key stages of the trial
This article presents a graphical tool depicting the time sequence and blinding 
status of the different stages of a cluster randomised trial, together with examples 
to help researchers describe the storyline of such trials
Our graphical tool should be used at both the protocol and report writing stages to 
clarify the trial process and to help identify the risk of bias
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judgment from the assessor or is directly reported by 
the participant.
To assess the risk of bias, an accurate description 
of the distinct procedures is required, but despite 
existing recommendations,4  the reporting of both the 
recruitment process and the blinding status for par-
ticipants and trial staff is often incomplete.9 10 To 
help researchers with this description, we developed 
a graphical tool depicting the sequence and blinding 
of the different steps of a cluster randomised trial 
and whether the intervention arms are treated the 
same or not.
Development of the timeline cluster tool
The working group consisted of AC, SK, CL, and SE, all 
statisticians who have been involved in the planning, 
analysis, and reporting of cluster randomised trials as 
well as in methodological and statistical research on 
this design. Early in 2015, AC initiated a first version of 
the graphical tool from real cluster randomised trials. In 
August 2015, the working group attended a one day 
meeting to discuss this first version of the graphical 
tool. During the meeting, decisions were made by infor-
mal consensus regarding stages that need to be reported 
and how to better represent cluster and participant lev-
els as well as about blinding. After this first meeting, AC 
developed a second version of the graphical tool. ET 
helped AC in the design of this second version (and later 
versions). Documents were shared by email, and sev-
eral email iterations took place. Feedback was 
requested from the whole working group. We also incor-
porated feedback received from a presentation of the 
graphical tool at a meeting on current developments in 
cluster randomised trials and stepped wedge designs 
held in London under the auspices of the Royal Statisti-
cal Society in October 2015 (all members of the working 
group were part of the 31 attendees at this meeting). 
Pilot use of the tool was performed by chief investiga-
tors (n=3) and statisticians (n=2) on published or ongo-
ing cluster trials. The latest version of the Timeline 
cluster tool also takes into account editors’ and reviewers’ 
comments.
the timeline cluster tool
The Timeline cluster tool consists of a diagram and 
table displayed together (see figs 1-3 for examples). 
The diagram represents the sequence of stages of the 
trial process using successive boxes. Randomisation 
of clusters is a key stage and is symbolised by a two 
way black arrow. All the following stages should be 
reported when applicable: the identification and 
recruitment of both clusters and participants, rando-
misation, intervention delivery, and baseline and 
outcome assessment of participants. The cluster level 
is symbolised by a ring and the participant level by a 
stick figure. Blinding status is depicted by the back-
ground colour of the boxes. If blinding is complete 
(all involved protagonists are blinded to allocation), 
the background of the box is black. If blinding is lack-
ing (no involved protagonist is blinded), the back-
ground is white. If blinding is partial (blinding has 
been used to avoid bias, but not all protagonists are 
blinded to allocation), the background is grey. Exam-
ples of partial blinding include when some protago-
nists are blinded but others are not or when some 
protagonists are masked to the hypotheses of the 
trial. Also stages occurring before randomisation 
must have a black background not because of 
blinding (as no allocation has been made) but 
because these steps cannot be affected by subsequent 
allocation. When the control arm receives usual care 
only, neither symbol appears on the right of the box 
because nothing is added by the trial at this stage for 
clusters or participants compared with standard care. 
Stages that differ between the intervention arms (at 
least intervention delivery stage) should be repre-
sented by two separate rectangles drawn on each side 
of the dotted line. The table should at least provide 
justification for blinding status and other essential 
details to interpret the diagram, such as the informa-
tion provided to participants within each arm. The 
remaining information added in the table is at the 
user’s discretion and replaces what would have been 
reported in the full text.
Examples
A cluster randomised trial with identification and 
recruitment of participants before randomisation
The PEACH trial11 12  is a cluster randomised trial of 
coaching of people with type 2 diabetes by practice 
nurses. The Timeline cluster diagram for this trial 
(fig 1) shows that first the clusters are identified and 
recruited, then participants are identified and 
recruited, and then baseline characteristics are col-
lected before the clusters are randomised. All these 
stages are performed before randomisation, so the cor-
responding rectangles have black backgrounds and 
there is no risk of recruitment bias. For the interven-
tion delivery, in the experimental arm the rectangle 
has a ring plus a stick figure to the right, and in the 
control arm, neither symbol. We can conclude that the 
intervention in the experimental arm is delivered at 
both cluster and individual levels and consists of 
usual care in the control arm. The background of the 
rectangle is white because of no blinding at that stage. 
The table confirms no blinding for general practi-
tioners, practice nurses, and participants, so we can-
not exclude performance bias. Finally, blinding is 
complete for the outcome, change in glycated haemo-
globin (HbA1c) level from baseline to 18 months; there 
is no risk of detection bias. The equivalent description 
is about 700 words in the protocol publication11  and 
600 words in the trial report.12
A cluster randomised trial with identification and 
recruitment of participants after randomisation
Figure 2  is the Timeline cluster diagram for a cluster 
randomised trial evaluating a hip protector to reduce 
hip fractures in older adults.13  Before randomisation, 
clusters are identified and recruited, then participants 
are identified and assessed. After randomisation, par-
ticipants are recruited without blinding because 
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 recruiters and participants are aware of the allocation 
and there is a risk of recruitment bias. Blinding is lack-
ing for the intervention delivery targeted at the indi-
vidual level in the experimental arm and consisting of 
usual care in the control arm, leading to possible 
 performance bias. Blinding is complete for the pri-
mary outcome, hip  fracture recorded at the participant 
level and documented by radiographs. The potential 
for recruitment bias is confirmed by the trial results, 
with a higher rate of consent and a lower proportion of 
participants with a history of falls or severe cognitive 
impairment at baseline in the control arm compared 
with the experimental arm.13
A cluster randomised trial with identification and 
recruitment of participants after randomisation 
with measures to prevent bias
The ELECTRA trial14  is a cluster randomised trial of a 
specialist nurse intervention to reduce unscheduled 
asthma care in a multiethnic area. Even though the 
identification, recruitment, and baseline assessment of 
individual participants are performed after randomisa-
tion of clusters, rectangles for these stages all have a 
black background because some measures are used to 
obtain complete blinding and thus prevent recruitment 
bias (fig 3). Further details provided in the table indi-
cate that a blinded researcher is used to identify and 
recruit participants. There is no blinding for the inter-
vention, targeted first at the cluster level before partici-
pant recruitment, then at the participant level after 
participant recruitment in both study arms. Some mea-
sures are used to avoid detection bias: general practi-
tioners who complete patient records are not blinded, 
but researchers who extract the primary outcome from 
the general practice records are blinded; this partial 
blinding for outcome assessment is represented by the 
rectangle’s grey background.
Comparison with other graphical representations
The Timeline cluster diagram is distinct from the Con-
solidated Standards of Reporting Trials (CONSORT) 
flowchart,4  which shows the flow of clusters and partic-
ipants by number approached, randomly assigned, 
receiving the allocated intervention, and included in 
the analysis for the primary outcome, together with the 
justification for losses and exclusions. The flowchart 
does not provide information on the chronology of the 
different stages or blinding of stages. In brief, the CON-
SORT flowchart is the “How many” and “Why (some 
participants are excluded)” of the trial, whereas the 
Timeline cluster diagram is the “When” and “How.” Our 
graphical tool is also distinct from other proposed dia-
grams that aim to better describe complex interventions 
either to clarify the timing and differences between 
arms of their different components (PaT plot method)15 
or to depict interactions between intervention providers 
at several levels (cascade diagram).16 These diagrams 
provide more detail about the intervention delivery 
stage only and are useful to enable reproducibility of 
tested interventions. All these graphical methods are 
complementary.
Usual care
Identication1
Coach programme
Stage level
Intervention delivery7a
1 Cluster identi
cation
The study team identies general practitioners (GPs) from the membership lists of Divisions of
General Practice in the state of Victoria in Australia
2 Cluster recruitment
All GPs on the membership list from practices that employ at least one practice nurse (PN) are
invited by post. The research team visits the GPs expressing their intention to participate and
provides an oral explanation of the study in detail, along with a complete, written information
pack. Written consent is obtained from GPs and PNs (not all GPs from the practice need to
consent to participate for the practice to be included in the study)
3 Participant identi
cation
Participating GPs obtain a list of all eligible patients from the practice electronic database.
GPs then apply the eligibility criteria
4 Participant recruitment
An information pack is mailed to a random sample of a maximum of 40 eligible patients for
each practice. For all patients who indicate an interest to participate, their details are
forwarded to their GP’s practice, then the PN contacts the patient to arrange a face-to-face
interview. Further rounds of randomly assigned mailing continue until at least six patients per
practice are recruited or the practice list is exhausted. At face-to-face interviews with the PN,
(i) the study is fully explained to the patient and (ii) written consent is obtained
5 Participant baseline assessment
Performed by the PN during the face-to-face interview aer consent is obtained. Glycated
haemoglobin (HbA1c) is measured at the patient’s local laboratory
7a Intervention delivery
PNs receive a two day training in the COACH programme (goal focused telephone coaching) and
then apply the COACH programme to participants from their practice combined with usual care
from the GP. No blinding for GP, PNs, and patients
7b Usual care
Patients receive usual care. No blinding for GP, PNs, and patients
8 Participant outcome assessment
Mean absolute change in HbA1c level between baseline and 18 months is measured by the
same local laboratory as for baseline assessment*; if not completed, the closest HbA1c level
between 15 and 21 months is obtained from patient medical records or pathology provider.
Other outcome data are collected by an independent blinded research assistant
* We used the protocol and report of the trial to apply the Timeline cluster tool post hoc for illustrative purpose.
We assumed that those who performed determination of HbA1c were blinded although this is neither clearly
specied in the protocol nor in the report
6 Randomisation
The randomisation schedule is generated by an independent statistician from the research
team, with blinding to the identity of the GP. The allocation sequence is computer-generated
by block randomisation with random block sizes (of 2 and 4). Randomisation is stratied on
the organisational and nancial arrangements of GPs (fee-for-service private practice or state
government-funded community health centre status) and whether GPs are participating in the
National Primary Care Collaborative Program. Clusters are randomised one aer the other, once
participants are recruited. Following randomisation, GPs are informed by a letter from the chief
investigator of their group assignment
Usual care7b
Cluster
Blinding status
BlindingParticipant
Recruitment2
Identication3
Recruitment4
Baseline assessment5
Outcome assessment8
Partial blinding No blinding
6
Randomisation
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Fig 1 | Example of Timeline cluster diagram for cluster trial with no risk of recruitment bias: 
the PEACH trial, assessing coaching of people with type 2 diabetes by practice nurses11 12
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Flexibility of the timeline cluster tool
Our tool offers great flexibility for most cluster trial 
designs because stages can be added, repeated, or 
removed. For a cluster trial with no need to recruit 
participants because individual data are obtained 
from routinely collected data, as in the IRIS trial,17  the 
participant recruitment stage can be removed, with 
only the participant identification stage retained. 
Also, a given stage can be performed at different times 
depending on the intervention arm, as in the cluster 
trial of Cheyne and colleagues,18  which evaluated the 
use of an algorithm to diagnose active labour: women 
provided consent at admission in the experimental 
arm and on the postnatal wards in the control arm. 
This situation of a differential timing for participant 
recruitment could be represented by a participant 
recruitment box before intervention delivery in the 
experimental arm and after intervention delivery in 
the control arm. For a cluster trial with a repeated 
cross sectional design as the one reported by Murphy 
and colleagues,19  in which clusters are followed over 
time but participants change during the trial, the 
need to repeat the identification and recruitment of 
participants after intervention delivery could be rep-
resented by a loop starting and ending on the central 
dotted line of the diagram. A cluster crossover trial 
such as REPHVIM trial20 could be depicted by adding 
two crossing and ascending arrows to depict the 
switch from one intervention to the other at the end of 
the first period.
See the supplementary file for Timeline cluster dia-
grams corresponding to these four trials.
Discussion
We have proposed a simple and adaptable graphical 
approach to represent the chronology, blinding, and 
differences between arms in a cluster randomised trial 
that allows a quick overview of a given study. The Time-
line cluster diagram can be useful at both the design 
and the reporting stages of a cluster randomised trial. 
At the design stage, the tool might help researchers 
identify threats to internal validity and consider ways to 
improve the methodology of their trial, such as use of a 
recruiter blinded to allocation status. It could also help 
to adequately implement the trial process in each clus-
ter. At the reporting stage, a more detailed version of the 
tool can be provided by completing the table with what 
actually happened during the trial. Providing a precise 
and adequate description of what was done will help 
readers understand the timeline of a trial and appraise 
the risk of bias. We recommend that future users pro-
vide an interpretation of the Timeline cluster diagram 
in the Discussion section of their trial report. Most 
often, risk of bias depends on the amount of boxes with 
black, grey, and white backgrounds; indeed, the more 
black backgrounds, the lower the risk of bias, and the 
more white backgrounds, the greater the risk of bias, 
with grey reflecting intermediate or possible risk of 
bias. However, background colour is not completely 
associated with the risk of bias level: if the background 
colour is black, there is no risk of bias at the corre-
sponding stage, but if the background colour is grey or 
white, the risk of bias must be assessed in the light of 
other information. For example, if the primary outcome 
is survival, and outcome assessors of vital status are not 
blinded to allocation, the box for outcome assessment 
Usual care
Identication1
Hip protector
Stage level
Intervention delivery7a
1 Cluster identication
Community based healthcare centres in the southern and central parts of Finland are
approached. In each centre that agrees to participate in the trial, the local research coordinator
identies treatment units that care for older adults at high risk of hip fracture (geriatric long
stay facilities or outpatient care units for supported living at home)
2 Cluster recruitment
Research coordinator takes consent from treatment unit
3 Participant identication
All eligible participants in the treatment unit are identied by the research coordinator with the
help of the other caregivers
4 Participant baseline assessment
Baseline data for eligible participants are collected by the research coordinator with the help
of the other caregivers from the treatment unit
5 Randomisation
Randomisation with a 1:2 ratio (allocating more clusters in the control group) is performed at
treatment unit level by an independent physician, at the President Urho Kaleva Kekkonen
Institute for Health Promotion Research, by using sealed envelopes. All clusters (treatment
units) from a given healthcare centre are randomised at once as soon as participant
identication is completed within this centre
7a Intervention delivery
Participants wear a hip protector whenever they are on their feet. No blinding for care providers
and participants
7b Usual care
None of the participants use a hip protector. No blinding for care providers and participants
8 Participant outcome assessment
Fracture of the hip or the proximal femur prospectively recorded during the study and conrmed
by radiographs*
* We used the report of the trial to apply the Timeline cluster tool post hoc for illustrative purposes. We assumed that
those who read the radiographs were blinded although this is not clearly specied in the report
6 Participant recruitment
Participants (or their family members) receive information and provide written consent.
During the trial, participants who have consented but drop out because of death, new inability
to walk, hip fracture, or withdrawal of consent, are replaced, whenever possible, by new
eligible participants from a waiting list. No blinding for recruiters and participants
Usual care7b
Cluster
Blinding status
BlindingParticipant
Recruitment2
6
Identication3
Baseline assessment4
Outcome assessment8
Partial blinding No blinding
5
Randomisation
Tr
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Recruitment
Fig 2 | Example of Timeline cluster diagram for cluster trial with risk of recruitment bias: 
cluster trial evaluating a hip protector to reduce hip fractures in older adults13
the bmj | BMJ 2016;354:i4291 | doi: 10.1136/bmj.i4291
RESEARCH
5
must have a white background even though there is 
only low risk of detection bias.
Weaknesses in design and conduct as well as incom-
plete reporting of biomedical studies are important lead-
ing causes of research waste.21 22 Risk of bias, specifically 
recruitment bias, is a problem in cluster randomised 
trials, with remaining room for improvement. We believe 
that our graphical approach could help achieve better 
management and reporting of cluster randomised trials, 
allowing for an informed assessment of the risk of bias. 
We have received positive feedback from the investiga-
tors and statisticians who have used the current version 
of the Timeline cluster tool, but we anticipate that some 
further enhancement will probably be required. There-
fore, we encourage suggestions from readers and feed-
back from the practical experience of future users.
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